ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: $266 million, up 26% year-over-year.

Cortrophin Gel Revenues: $117.1 million, a 43% increase year-over-year and 56% quarter-over-quarter.

Adjusted EBITDA: $71.6 million, up 32% year-over-year.

ILUVIEN Revenues: $18.7 million, down 16% year-over-year due to timing of international shipments.

Generics Revenues: $99.1 million, a 10% increase year-over-year.

Adjusted Non-GAAP EPS: $2.21, compared to $1.80 in the prior year.

Cash Position: $360.2 million in unrestricted cash, up $74.6 million from the end of 2025.

2Strategic Updates and Business Highlights

ANI is focused on transforming into a leading rare disease company, with significant investments in expanding its sales force by 50% to approximately 180 representatives.

The company reported strong growth in Cortrophin Gel, driven by existing specialties and the recent expansion into gout treatment.

The Harmony intellectual property out-licensing deal contributed $17.7 million in revenue.

The company launched 12 generics in 2026 and plans to launch at least 15 by year-end.

Continued emphasis on disciplined capital allocation to support organic growth and evaluate inorganic opportunities in the rare disease space.

3Forward Guidance and Outlook

2026 Total Revenue Guidance: Revised to $1.08 billion to $1.14 billion, reflecting 26% growth year-over-year.

Cortrophin Gel Revenue Guidance: Revised to $520 million to $540 million, maintaining expectations for the second half of the year.

Adjusted Non-GAAP EBITDA Guidance: Expected to be between $285 million and $300 million.

Q3 Cortrophin Revenue Forecast: Anticipated to be between $143 million and $153 million, with expectations for a stronger Q4 driven by the full deployment of the gout expansion sales force.

4Bad News, Challenges, or Points of Concern

ILUVIEN's revenue decline raises concerns about its market performance and potential long-term growth.

The company faced challenges in Q1 related to insurance reverification issues, although these were reportedly resolved by Q2.

Despite strong growth indicators, there is caution regarding the potential impact of payer dynamics and competitive pressures in the rare disease space.

The guidance revision reflects actual performance in the first half of 2026, raising questions about the sustainability of growth momentum.

5Notable Q&A Insights

Management confirmed that "new cases initiated" refers to prescriptions written, and they are seeing strong demand generation from the gout expansion.

There was no significant lag in prescription fulfillment reported, and the company is confident in its ability to support prescribers through the reimbursement process.

The expansion into gout is expected to significantly impact Q4 revenues, with a larger sales force and positive early indicators from the expansion.

Management emphasized that the addressable market for Cortrophin remains largely underpenetrated, indicating a long-term growth opportunity despite current challenges. Overall, ANI Pharmaceuticals demonstrated strong financial performance in Q2 2026, with a clear focus on expanding its rare disease business, particularly through Cortrophin Gel. However, the company faces ongoing challenges in the market and must navigate competitive pressures and payer dynamics as it moves forward.